• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
'Press Releases' Section describes most distant clients with latest product-specific, company-related updates is a key value addition to our members because they can use this platform as the easiest, earlier and the most effective means to get noticed quickly.

Our press release programs work hand in hand with our SEO programs to provide a rock solid positioning in all major search engines so as to contemplate the visibility of your message for Worldwide Pharmaceutical industry.
ARTiFACTS, DPAL

New initiative launches to attack problem of substandard generic drug distribution

ARTiFACTS, creator of the world's first blockchain-based platform for scientific and academic research, today announced a partnership with the Distributed Pharmaceutical Analysis Lab (DPAL) at the University of Notre Dame to develop a prototype solution for tracking pharmaceutical chain-of-custody information in real-time using distributed ledger technology.

Read more →
CK2 inhibitor

Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945)

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, the positive efficacy and safety results from an investigator-initiated, Phase 2 clinical trial of Silmitasertib in approximately 20 patients with moderate COVID-19.

Read more →
DreaMed Diabetes

DreaMed Receives FDA Clearance for its Type 2 Diabetes AI-based Clinical Decision Support System

DreaMed Diabetes AI LTD. (“DreaMed” or the “Company”), a developer of the Advisor Pro Al Clinical Decision Support System expert-care platform for diabetes,  that it has received its 4th U.S Food and Drug Administration (FDA) clearance that expands the platform's target population to patients with both type 1 and type 2 diabetes.

Read more →